Hepatitis C Infection in World Trade Center Responders

Status Completed

Clinical Trial Summary

This study provides Hepatitis C virus screening to the members of the World Trade Center Health Program followed at the Icahn School of Medicine at Mount Sinai born during 1945-1965, and linkage to care for those found infected. The study will also determine if exposure to human remains, blood and/or bodily fluids during the World Trade Center Health Program activities are associated with Hepatitis C virus infection. These findings would be relevant to the larger United States population, especially to persons born during 1945-1965 who are at high risk of Hepatitis C virus infection.

Clinical Trial Description

The purpose of the project is to determine if the World Trade Center Health Program cohort is at an increased risk of Hepatitis C virus infection, determine if human exposure to human remains, blood and/or body fluids during the World Trade Center recovery activities is associated with increased risk of Hepatitis C virus infection, and to determine if referral to a co-located site for Hepatitis C virus care is associated with improved linkage to Hepatitis C virus care in the members of the World Trade Center Health Program born during 1945 through 1965. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02982993
Study type	Observational
Source	Icahn School of Medicine at Mount Sinai
Contact
Status	Completed
Phase
Start date	December 2016
Completion date	July 12, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01771653` - Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection	N/A
Recruiting	`NCT03601546` - Feasibility of Implementing a Cohort of People Living With Hepatitis C in Vietnam
Completed	`NCT02362217` - A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination	Phase 1
Completed	`NCT00513461` - Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection	Phase 2
Active, not recruiting	`NCT02143401` - Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	Phase 1
Completed	`NCT02247401` - Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt	Phase 3
Completed	`NCT02582632` - A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults	Phase 3
Terminated	`NCT01532908` - Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C	Phase 2
Recruiting	`NCT01754961` - Effects of Vitamin D on Inflammation in Liver Disease	Phase 2
Terminated	`NCT01465516` - Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir	N/A
Completed	`NCT01265511` - Study of SCY-635, Pegasys and Copegus in Hepatitis C	Phase 2
Completed	`NCT04042740` - Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection	Phase 2
Not yet recruiting	`NCT05601518` - Efficacy and Safety of Coblopasvir Hydrochloride Capsules Combined With Sofosbuvir Tablets for the Treatment of Chronic HCV Infection: A Prospective, Multi-center Real-world Study.
Terminated	`NCT02429583` - Effects of Persistent Innate Immune Activation on Vaccine Efficacy	Phase 4
Not yet recruiting	`NCT05506475` - Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in Vietnam
Terminated	`NCT01841502` - Interaction Between Paroxetine and Telaprevir	Phase 2
Withdrawn	`NCT02112630` - Boceprevir in End Stage Renal Disease (ESRD)	N/A
Completed	`NCT02076100` - Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)	Phase 1
Completed	`NCT01803308` - A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection	Phase 1
Terminated	`NCT01560468` - Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection	Phase 1